Likewise, our results show that human GBM-derived primary ECs exhibit robust resistance to anti-VEGF/VEGFR-2 treatment, challenging VEGF as the primary, sole target for anti-vascular cancer therapy. The gene discussed is VEGFA; the disease is vascular cancer.